Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Stivarga (Regorafenib; Bayer/Amgen) Drug Analysis 2016-2025 - ResearchAndMarkets.com

Research and Markets
Posted on: 15 Feb 18

The "Drug analysis: Stivarga" drug pipelines has been added to ResearchAndMarkets.com's offering.

Stivarga (regorafenib; Bayer/Amgen) is a novel diphenylurea oral multikinase inhibitor of angiogenic (vascular endothelial growth factor receptor [VEGFR], platelet-derived growth factor receptor [PDGFR], and fibroblast growth factor receptor [FGFR]), stromal, and oncogenic (KIT, RET, and B-Raf) kinases.

VEGF-directed agents are a key target in colorectal cancer following the success of Avastin (bevacizumab; Genentech/Roche/Chugai). The anti-angiogenic effect of Stivarga was demonstrated in vivo by dynamic contrast-enhanced magnetic resonance imaging (MRI). In such in vivo models,

Stivarga demonstrated anti-angiogenic activity in animal tumor models, inhibition of tumor growth, and antimetastatic activity. A significant reduction in tumor microvessel area was observed in a human colorectal xenograft after dosing.

Key Topics Covered:

Product Profiles

Stivarga: Colorectal cancer (CRC)

Stivarga: Hepatocellular carcinoma (HCC)

List of Figures

Figure 1: Stivarga for colorectal cancer - SWOT analysis

Figure 2: Drug assessment summary of Stivarga for colorectal cancer

Figure 3: Drug assessment summary of Stivarga for colorectal cancer

Figure 4: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25

Figure 5: Stivarga for HCC - SWOT analysis

Figure 6: Drug assessment summary of Stivarga for HCC

Figure 7: Drug assessment summary of Stivarga for HCC

List of Tables

Table 1: Stivarga drug profile

Table 2: Stivarga pivotal trial data in colorectal cancer

Table 3: Stivarga ongoing trials in colorectal cancer

Table 4: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25

Table 5: Patients treated with Stivarga across the US, Japan, and five major EU markets, by country, 2016-25

Table 6: Stivarga drug profile

Table 7: Stivarga pivotal trial data in HCC

Table 8: Stivarga Phase II data in HCC

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/53tzzk/stivarga?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180215006154/en/

Business Wire
www.businesswire.com

Last updated on: 15/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.